Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 19/20 | 0.48 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.44 |
| ▸ | MMP2 | P08253 | 3/20 | 0.44 |
| ▸ | MMP7 | P09237 | 3/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | MMP14 | P50281 | 2/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8212390 | 0.83 | TP53 (0.47) | ADAM17 | |
| SCHEMBL8274851 | 0.82 | ADAM17 (0.69) | ADAM17ADAM10MMP2MMP7MMP9 | |
| SCHEMBL8222460 | 0.81 | ADAM17 (0.68) | ADAM17ADAM10MMP2MMP7MMP9 | |
| SCHEMBL23419009 | 0.80 | KMT2A (0.58) | NPY5R | |
| SCHEMBL8216093 | 0.79 | MGLL (0.44) | ADAM17NPY5R | |
| SCHEMBL16357674 | 0.79 | MGLL (0.44) | ADAM17NPY5R | |
| SCHEMBL8212418 | 0.76 | TAAR1 (0.49) | ADAM17 | |
| SCHEMBL8218401 | 0.76 | MAPT (0.53) | — | |
| SCHEMBL16357117 | 0.75 | MAPT (0.41) | — | |
| SCHEMBL8218258 | 0.75 | GCGR (0.45) | ADAM17ADAM10MMP2MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7553864-B2 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553864-B2 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | ADAM17 4/4885ADAM10 9/4885MMP2 45/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | ADAM17 11/4885ADAM10 13/4885MMP2 40/4885 |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, PCSK9, ALPI | ADAM17 14/4885ADAM10 16/4885MMP2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.